Patents by Inventor Saddek Mohand-Said

Saddek Mohand-Said has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9353162
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: May 31, 2016
    Assignees: NOVARTIS AG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Thirry Léveillard, Jose Alain Sahel, Saddek Mohand-Said, Olivier Poch, David Hicks, Carlos Alvarez
  • Patent number: 8957043
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: February 17, 2015
    Assignees: Novartis AG, Universite de Strasbourg
    Inventors: Thierry Leveillard, Jose Alain Sahel, Saddek Mohand-Said, David Hicks
  • Publication number: 20130287738
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Application
    Filed: June 4, 2013
    Publication date: October 31, 2013
    Applicants: UNIVERSITE DE STRASBOURG, NOVARTIS AG
    Inventors: Thierry LEVEILLARD, Jose Alain SAHEL, Saddek MOHAND-SAID, David HICKS
  • Patent number: 8518695
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: August 27, 2013
    Assignees: Novartis AG, Universite de Strasbourg
    Inventors: Thierry Leveillard, Jose Alain Sahel, Saddek Mohand-Said, David Hicks
  • Patent number: 8394756
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: March 12, 2013
    Assignees: NOVARTIS AG, Universite de Strasbourg
    Inventors: Thierry Leveillard, Jose Alain Sahel, Saddek Mohand-Said, David Hicks
  • Publication number: 20120108657
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Application
    Filed: January 11, 2012
    Publication date: May 3, 2012
    Applicant: NOVARTIS AG
    Inventors: Thierry LÉVEILLARD, José Alain SAHEL, Saddek MOHAND-SAID, David HICKS
  • Publication number: 20120108523
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with nonsufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Application
    Filed: January 11, 2012
    Publication date: May 3, 2012
    Applicant: NOVARTIS AG
    Inventors: Thierry LÉVEILLARD, José Alain SAHEL, Saddek MOHAND-SAID, David HICKS
  • Patent number: 8114849
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: February 14, 2012
    Assignees: Novartis AG, Universite de Strasbourg
    Inventors: Thierry Leveillard, Jose Alain Sahel, Saddek Mohand-Said, David Hicks
  • Patent number: 8071745
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: December 6, 2011
    Assignees: Novartis AG, Universite de Strasbourg
    Inventors: Thierry Léveillard, José Alain Sahel, Saddek Mohand-Said, David Hicks
  • Publication number: 20110105411
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Application
    Filed: January 6, 2011
    Publication date: May 5, 2011
    Inventors: Thirry Leveillard, Jose Alain Sahel, Saddek Mohand-Said, Olivier Poch, David Hicks, Carlos Alvarez
  • Patent number: 7795387
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, chroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed 2Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recongnize this protein, and methods for diagnosing such conditions.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: September 14, 2010
    Assignees: Novartis AG, Universite de Strasbourg
    Inventors: Thierry Léveillard, José Alain Sahel, Saddek Mohand-Said, David Hicks
  • Publication number: 20090215679
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Application
    Filed: May 12, 2005
    Publication date: August 27, 2009
    Applicants: Novartis AG, Institut National de la Sante et de la Recherche Medicale
    Inventors: Thirry Leveillard, Jose Alain Sahel, Saddek Mohand-Said, Olivier Poch, David Hicks, Carlos Alvarez
  • Publication number: 20090062188
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Application
    Filed: April 25, 2007
    Publication date: March 5, 2009
    Inventors: Thierry Leveillard, Jose Alain Sahel, Saddek Mohand-Said, David Hicks
  • Publication number: 20080004231
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Application
    Filed: April 25, 2007
    Publication date: January 3, 2008
    Inventors: Thierry Leveillard, Jose Sahel, Saddek Mohand-Said, David Hicks
  • Publication number: 20040204350
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, chroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed 2Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recongnize this protein, and methods for diagnosing such conditions.
    Type: Application
    Filed: April 2, 2004
    Publication date: October 14, 2004
    Inventors: Thierry Leveillard, Jose Alain Sahel, Saddek Mohand-Said, David Hicks